 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || budesonide inhalation solution (AQ001S) / Aquilon
Trial completion: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Jun 9, 2023
P1/2, N=23, Completed, Sponsor: Aquilon Pharmaceuticals S.A.
Recruiting --> Completed
- | budesonide inhalation solution (AQ001S) / Aquilon
Enrollment change, Trial termination: SIROCCO-1: Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms (clinicaltrials.gov) - Jan 6, 2023
P2, N=21, Terminated, Sponsor: Aquilon Pharmaceuticals S.A.
Recruiting --> Completed N=99 --> 21 | Recruiting --> Terminated; Lack of patient to recruit
- || budesonide inhalation solution (AQ001S) / Aquilon
Trial completion date, Trial primary completion date: SIROCCO-1: Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms (clinicaltrials.gov) - Nov 3, 2022
P2, N=99, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
N=99 --> 21 | Recruiting --> Terminated; Lack of patient to recruit Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Dec 2022
- | budesonide inhalation solution (AQ001S) / Aquilon
Trial completion date, Trial primary completion date: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Nov 3, 2022
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: May 2022 --> Dec 2022 Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Jan 2023
- ||| budesonide inhalation solution (AQ001S) / Aquilon
Enrollment open, Trial completion date, Trial primary completion date: SIROCCO-1: Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms (clinicaltrials.gov) - Feb 28, 2022
P2, N=99, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Trial completion date: May 2022 --> Jan 2023 | Trial primary completion date: May 2022 --> Jan 2023 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Dec 2021 --> May 2022
- || budesonide inhalation solution (AQ001S) / Aquilon
Trial completion, Enrollment change: BORA: Single-dose AQ001S PK Study in Healthy Volunteers (clinicaltrials.gov) - Feb 21, 2022
P1, N=29, Completed, Sponsor: Aquilon Pharmaceuticals S.A.
Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Dec 2021 --> May 2022 Recruiting --> Completed | N=20 --> 29
- | budesonide inhalation solution (AQ001S) / Aquilon
Trial completion date, Trial primary completion date: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Feb 15, 2022
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Recruiting --> Completed | N=20 --> 29 Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> May 2022
- || budesonide inhalation solution (AQ001S) / Aquilon
New P1 trial: BORA: Single-dose AQ001S PK Study in Healthy Volunteers (clinicaltrials.gov) - Dec 7, 2021
P1, N=20, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
- || budesonide inhalation solution (AQ001S) / Aquilon
Trial initiation date: SIROCCO-1: Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms (clinicaltrials.gov) - Nov 3, 2021
P2, N=99, Not yet recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Trial completion date: Nov 2021 --> May 2022 | Trial primary completion date: Nov 2021 --> May 2022 Initiation date: Aug 2021 --> Nov 2021
- |||| budesonide inhalation solution (AQ001S) / Aquilon
New P2 trial: SIROCCO-1: Clinical Trial to Assess the Efficacy and Safety of Inhaled AQ001S in the Management of Acute COVID-19 Symptoms (clinicaltrials.gov) - Aug 11, 2021
P2, N=99, Not yet recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
- || budesonide inhalation solution (AQ001S) / Aquilon
Enrollment open: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Jul 27, 2021
P1/2, N=24, Recruiting, Sponsor: Aquilon Pharmaceuticals S.A.
Initiation date: Aug 2021 --> Nov 2021 Not yet recruiting --> Recruiting
- | budesonide inhalation solution (AQ001S) / Aquilon
New P1/2 trial: BOREAS: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics (clinicaltrials.gov) - Jun 21, 2021
P1/2, N=24, Not yet recruiting, Sponsor: Aquilon Pharmaceuticals S.A.